

Osteoarthritis Pain Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/ODFD5C7FEB0EN.html>

Date: November 2017

Pages: 136

Price: US\$ 3,480.00 (Single User License)

ID: ODFD5C7FEB0EN

Abstracts

Report Summary

Osteoarthritis Pain Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Osteoarthritis Pain Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Osteoarthritis Pain Drugs 2013-2017, and development forecast 2018-2023

Main market players of Osteoarthritis Pain Drugs in EMEA, with company and product introduction, position in the Osteoarthritis Pain Drugs market

Market status and development trend of Osteoarthritis Pain Drugs by types and applications

Cost and profit status of Osteoarthritis Pain Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Osteoarthritis Pain Drugs market as:

EMEA Osteoarthritis Pain Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023)

Europe

Middle East

Africa

EMEA Osteoarthritis Pain Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oral
Injection
External

EMEA Osteoarthritis Pain Drugs Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals
Clinics
Other

EMEA Osteoarthritis Pain Drugs Market: Players Segment Analysis (Company and
Product introduction, Osteoarthritis Pain Drugs Sales Volume, Revenue, Price and
Gross Margin):

Abbott Laboratories
Johnson & Johnson
Novartis International
Pfizer
Abiogen Pharma
Afferent Pharmaceuticals
Astellas Pharma
BioDelivery Sciences International
Crystal Genomics
Cytori Therapeutics
Daiichi Sankyo
Eli Lilly
Endo Pharmaceuticals Holdings
Horizon Pharma
ICEutica
Iroko Pharmaceuticals
Merck
Nuvo Research
Regeneron Pharmaceuticals
Sanofi
SantoSolve

Techfields Pharma
Winston Pharmaceuticals
Yooyoung Pharmaceutical
Zynerba Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OSTEOARTHRITIS PAIN DRUGS

- 1.1 Definition of Osteoarthritis Pain Drugs in This Report
- 1.2 Commercial Types of Osteoarthritis Pain Drugs
 - 1.2.1 Oral
 - 1.2.2 Injection
 - 1.2.3 External
- 1.3 Downstream Application of Osteoarthritis Pain Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Other
- 1.4 Development History of Osteoarthritis Pain Drugs
- 1.5 Market Status and Trend of Osteoarthritis Pain Drugs 2013-2023
 - 1.5.1 EMEA Osteoarthritis Pain Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Osteoarthritis Pain Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Osteoarthritis Pain Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Osteoarthritis Pain Drugs in EMEA by Regions
 - 2.2.1 Consumption Volume of Osteoarthritis Pain Drugs in EMEA by Regions
 - 2.2.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Regions
- 2.3 Market Analysis of Osteoarthritis Pain Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Osteoarthritis Pain Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Osteoarthritis Pain Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Osteoarthritis Pain Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Osteoarthritis Pain Drugs in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Osteoarthritis Pain Drugs in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Osteoarthritis Pain Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Osteoarthritis Pain Drugs in EMEA by Types
 - 3.1.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in Europe
- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Osteoarthritis Pain Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Osteoarthritis Pain Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Osteoarthritis Pain Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Osteoarthritis Pain Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Osteoarthritis Pain Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 OSTEOARTHRITIS PAIN DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Osteoarthritis Pain Drugs in EMEA by Major Players
- 6.2 Revenue of Osteoarthritis Pain Drugs in EMEA by Major Players
- 6.3 Basic Information of Osteoarthritis Pain Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Osteoarthritis Pain Drugs Major Players
 - 6.3.2 Employees and Revenue Level of Osteoarthritis Pain Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 OSTEOARTHRITIS PAIN DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Abbott Laboratories

7.1.1 Company profile

7.1.2 Representative Osteoarthritis Pain Drugs Product

7.1.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories

7.2 Johnson & Johnson

7.2.1 Company profile

7.2.2 Representative Osteoarthritis Pain Drugs Product

7.2.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.3 Novartis International

7.3.1 Company profile

7.3.2 Representative Osteoarthritis Pain Drugs Product

7.3.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Novartis International

7.4 Pfizer

7.4.1 Company profile

7.4.2 Representative Osteoarthritis Pain Drugs Product

7.4.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Pfizer

7.5 Abiogen Pharma

7.5.1 Company profile

7.5.2 Representative Osteoarthritis Pain Drugs Product

7.5.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Abiogen Pharma

7.6 Afferent Pharmaceuticals

7.6.1 Company profile

7.6.2 Representative Osteoarthritis Pain Drugs Product

7.6.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Afferent Pharmaceuticals

7.7 Astellas Pharma

7.7.1 Company profile

7.7.2 Representative Osteoarthritis Pain Drugs Product

7.7.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma

7.8 BioDelivery Sciences International

7.8.1 Company profile

7.8.2 Representative Osteoarthritis Pain Drugs Product

7.8.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of

BioDelivery Sciences International

7.9 Crystal Genomics

7.9.1 Company profile

7.9.2 Representative Osteoarthritis Pain Drugs Product

7.9.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Crystal Genomics

7.10 Cytori Therapeutics

7.10.1 Company profile

7.10.2 Representative Osteoarthritis Pain Drugs Product

7.10.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Cytori Therapeutics

7.11 Daiichi Sankyo

7.11.1 Company profile

7.11.2 Representative Osteoarthritis Pain Drugs Product

7.11.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo

7.12 Eli Lilly

7.12.1 Company profile

7.12.2 Representative Osteoarthritis Pain Drugs Product

7.12.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly

7.13 Endo Pharmaceuticals Holdings

7.13.1 Company profile

7.13.2 Representative Osteoarthritis Pain Drugs Product

7.13.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Endo Pharmaceuticals Holdings

7.14 Horizon Pharma

7.14.1 Company profile

7.14.2 Representative Osteoarthritis Pain Drugs Product

7.14.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of Horizon Pharma

7.15 ICeutica

7.15.1 Company profile

7.15.2 Representative Osteoarthritis Pain Drugs Product

7.15.3 Osteoarthritis Pain Drugs Sales, Revenue, Price and Gross Margin of ICeutica

7.16 Iroko Pharmaceuticals

7.17 Merck

7.18 Nuvo Research

7.19 Regeneron Pharmaceuticals

7.20 Sanofi

- 7.21 SantoSolve
- 7.22 Techfields Pharma
- 7.23 Winston Pharmaceuticals
- 7.24 Yooyoung Pharmaceutical
- 7.25 Zynerva Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS

- 8.1 Industry Chain of Osteoarthritis Pain Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS

- 9.1 Cost Structure Analysis of Osteoarthritis Pain Drugs
- 9.2 Raw Materials Cost Analysis of Osteoarthritis Pain Drugs
- 9.3 Labor Cost Analysis of Osteoarthritis Pain Drugs
- 9.4 Manufacturing Expenses Analysis of Osteoarthritis Pain Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF OSTEOARTHRITIS PAIN DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach

- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Osteoarthritis Pain Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/ODFD5C7FEB0EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ODFD5C7FEB0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970